Author(s): Taylor DL, Woo ES, Giuliano KA
Abstract Share this page
Abstract The pharmaceutical industry is currently facing the challenge of maintaining increased efficiency and productivity while contending with a deluge of genomic and high-throughput screening data. To ease the bottlenecks at target validation and lead optimization, the industry must look to the living cell, the ultimate target of all drugs, as a source of new biological knowledge. This new 'cell-centric' perspective must integrate reagents that report on the state of molecular processes within the cell, automated detection and analysis of these processes, and cellular knowledge, building into a single platform.
This article was published in Curr Opin Biotechnol
and referenced in Journal of Antivirals & Antiretrovirals